SAN DIEGO, Calif. — Vironexis Biotherapeutics today announced encouraging clinical results from the ongoing SENTRY-CD19 study of VNX-101, its investigational, one-time in vivo immunotherapy, in patients with relapsed or refractory CD19-positive hematologic malignancies. VNX-101 is designed to turn a patient’s own liver into a “biofactory” capable of producing GP101, a...

New York, New York and Rockville, Maryland – OS Therapies, Inc. (NYSE American: OSTX) (“OS Therapies” or the “Company”), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided an update on global early market access regulatory coordination efforts being led by the U.K.’s Medicines and Healthcare products Regulatory Agency...

BRIDGEWATER, N.J. — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Supplemental New Drug Application (sNDA) for review of ARIKAYCE® (amikacin...